Vernal Keratoconjunctivitis Market is expected to accumulate a value of US$ 782.42 Million by registering a CAGR of 6%

The global Vernal Keratoconjunctivitis Market is expected to garner a market value of US$ 436.9 Million in 2023 and is expected to accumulate a market value of US$ 782.42 Million by registering a CAGR of 6% in the forecast period 2023-2033. One of the reasons driving the global market over the projection period is the rising incidence of conjunctivitis in emerging nations. The market for Vernal Keratoconjunctivitis registered a CAGR of 4% in the historical period 2017-2022.

Growth of the Vernal Keratoconjunctivitis market can be attributed to the rising prevalence of ophthalmic allergies. As per the World Allergy Organization Journal published in December 2020, 10 medical centers reported a prevalence of allergic rhinoconjunctivitis in children of 11.6%, while adolescents reported 15.4%. In addition to this, factors such as increased awareness amongst the medical community, patients, and individuals associated with patients is one of the key market driving factors responsible for the growth of the conjunctivitis market.

Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16207

Furthermore, the market growth is highly driven by the severely and rapidly increasing air pollution in the majority of cities across the world. The National Center for Biotechnology Information (NCBI) published a research study in 2016 that the critical reasons for the occurrence and worsening of allergic conjunctivitis are ambient air pollution and weather changes. Therefore, an increase in air pollution promotes the growth of the market.

Major regions across the globe are pushing the overall growth owing to the presence of positive reimbursement policies. For instance, Europe is accountable for a 22% market share due to the growing potential patient population in the region along with the growing use of sophisticated drugs. Based on the British Journal of Ophthalmology, in the United Kingdom, seasonal allergic conjunctivitis is widespread and one of the mild forms of allergic conjunctivitis. It accounts for 25 to 50 per cent of all ocular allergy cases, and it is predicted to affect between 10 to 15 percent of the population in the UK.

Key Takeaways from the Market Study

• From 2017-2022, the Vernal Keratoconjunctivitis market grew at CAGR of 4%.
• The global Vernal Keratoconjunctivitis market is expected to grow with a 6% CAGR during 2023-2033.
• As of 2033, the Vernal Keratoconjunctivitis market is expected to reach US$ 782.42 Million.
• According to the FMI analysis, Hospital pharmacies account for the largest market share.
• Tablets are expected to show the highest CAGR owing to the increasing demand for new approaches.
• North America is expected to possess 20% market share for the Vernal Keratoconjunctivitis market.
• The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.

Ask from Market Research Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-16207

“With the increasing prevalence and awareness of ocular allergies has significantly increased owing to several factors such as faster urbanization and a growing number of allergens.” says an FMI analyst

Market Competition

Key players in the Vernal Keratoconjunctivitis market are Allakos, iCo Therapeutics, Akari Therapeutics, and Santen.

• In March 2022, Visus Therapeutics Inc. announced the launch of the first of two pivotal phases 3 trials (BRIO-I and BRIO-II) for its lead asset, BRIMOCHOL PF, a topical preservative-free ophthalmic solution for treating presbyopia.

Key Segments Profiled in the Vernal Keratoconjunctivitis Industry Survey

Treatment:

• Mast Cell Stabilizers
• Antihistamines
• Nonsteroidal Anti-inflammatory Drugs – NSAIDs
• Topical Corticosteroids
• Cyclosporine
• Tacrolimus
• Others

Drug Type:

• Bertilimumab
• Verkazia
• Lodoxamide
• Tacrolimus
• Antolimab
• Nomacopan
• Others

For more Report Customization, connect with us at@ https://www.futuremarketinsights.com/customization-available/rep-gb-16207

Dosage form:

• Ointment
• Gel
• Tablets
• Others

Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa (MEA)

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:           

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube